LENZ Therapeutics, Inc. LENZ 深 沪
等待开盘 03-26 09:30:00 美东时间
9.07
+0.040
+0.44%
华盛通- 最 高9.39
- 今 开9.19
- 成交量 142.61万股
- 最 低 8.99
- 昨 收 9.03
- 总市值 2.84亿
- 52周最高 50.40
- 市盈率 静 --
- 换手率 4.56%
- 52周最低 8.85
- 委 比 -10.91%
- 总股本 3129.00万
- 历史最高 230.79
- 量 比 0.83
- 振 幅 4.43%
- 历史最低 3.92
- 每 手 1
- 风险率 9.52%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多LENZ Therapeutics Q4 EPS $(1.16) Misses $(0.96) Estimate, Sales $1.588M Miss $1.886M Estimate
LENZ Therapeutics (NASDAQ:LENZ) reported quarterly losses of $(1.16) per share which missed the analyst consensus estimate of $(0.96) by 20.83 percent. This is a 152.17 percent decrease over losses of $(0.46) per share
03-24 20:01
Earnings Scheduled For March 24, 2026
Companies Reporting Before The Bell • Fennec Pharmaceuticals (NASDAQ:FENC) is e...
03-24 19:11
Top Wall Street Forecasters Revamp LENZ Therapeutics Expectations Ahead Of Q4 Earnings
LENZ Therapeutics (NASDAQ:LENZ) to release Q4 earnings on 3/24. Analysts expect loss of 90 cents/share. Stock gained 5% on Monday. Analyst ratings and accuracy rates available on Benzinga.
03-24 04:32
Shares of pharmaceutical companies are trading lower amid overall market weakness due to the ongoing conflict in the Middle East.
Shares of pharmaceutical companies are trading lower amid overall market weakne...
03-06 03:56
New FDA-Approved Eye Drop Sparks Fresh Competition For LENZ Therapeutics' Drug
FDA approved Tenpoint's Yuvezzi eye drop for presbyopia, adding competition for LENZ's VIZZ as analysts say the recent stock drop may be overdone and see blockbuster potential ahead.
01-31 02:02
LENZ Therapeutics Reports VIZZ Net Product Revenue Of ~ $1.6M In Q4 2025; Over 20,000 Prescriptions Filled Through Q4 2025; Rapid Uptake By Prescribing ECPs With Over 6,500 Unique Prescribing ECPs; More Than 55% Prescribed Multiple Times In Q4 2025
LENZ Therapeutics, Inc. (NASDAQ:LENZ), a pharmaceutical company focused on the commercialization of VIZZ™ (aceclidine ophthalmic solution) 1.44%, the first and only aceclidine-based eye drop for the treatment
01-08 06:15
LENZ Therapeutics Acknowledges Adverse Event Reported To FDA; Says Patient Using VIZZ Experiences Retinal Tear, Cause Uncertain Due To Pre-Existing Risk Factors
LENZ Therapeutics, Inc. ("the Company") is aware of a recent adverse event report submitted to the U.S. Food and Drug Administration's ("FDA") Adverse Event Reporting System ("FAERS") database describing a retinal tear
2025-12-13 05:29
LENZ Therapeutics And Lotus Pharmaceutical Announces That Lotus Has Submitted A New Drug Application To South Korea's Ministry Of Food And Drug Safety For Vizz, Intended To Treat Presbyopia In Adults
LENZ Therapeutics, Inc. (NASDAQ:LENZ) and Lotus Pharmaceutical Co., Ltd. ("Lotus", TWSW Stock Code: 1795) today announced that Lotus has submitted a New Drug Application (NDA) to the Ministry of Food and Drug Safety
2025-12-01 21:33
LENZ Therapeutics shares are trading lower. The company reported Q3 financial results.
LENZ Therapeutics shares are trading lower. The company reported Q3 financial r...
2025-11-05 22:26
LENZ Therapeutics Q3 EPS $(0.59) Beats $(0.67) Estimate, Sales $12.500M Beat $6.828M Estimate
LENZ Therapeutics (NASDAQ:LENZ) reported quarterly losses of $(0.59) per share which beat the analyst consensus estimate of $(0.67) by 11.54 percent. This is a 55.26 percent decrease over losses of $(0.38) per share from
2025-11-05 21:06
